InMed Pharmaceuticals Inc. (NASDAQ: INM) shares improved greatly Tuesday, as the Vancouver-based pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announces positive results from a long-term in vivo preclinical Alzheimer’s Disease (‘AD’) study. In the study, INM-901 demonstrated a reduction in several plasma and brain markers of neuroinflammation, a recognized contributor to Alzheimer’s disease development and progression.
Results from the long-term study of INM-901 in a well-characterized Alzheimer’s disease model demonstrated the following:
Improved cytokine profile – INM-901 treated groups showed a dose-dependent and statistically significant reduction in plasma pro-inflammatory cytokines such as TNF-a, IL-1ß and INF-?. Cytokine networks, when deregulated, may contribute to tissue inflammation.
Reduction in neurodegeneration biomarker – INM-901 demonstrated a dose-dependent and statistically significant reduction in neurofilament light chain (‘NfL’) in the plasma for the high dose treated group. NfL is a protein that is released from neurons in response to injury or disease. NfL levels are used to assess cellular damage in neurodegenerative disease.
Study supported by mRNA data – mRNA assessments showed a reduction of several key neuroinflammatory genes in the brain, such as GFAP, CD-33 and TLR-2, further supporting the overall results from the study.
INM shares vaulted $2.09, or 4.2%, to $7.04.
